The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Open accessAbstract
In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. Download a PDF of the Research Summary. In a phase 3, double-blind, randomized trial, we assigned patients with COPD who had a blood eosinophil count of at least 300 per microliter and an elevated exacerbation risk despite the use of standard triple therapy to receive dupilumab (300 mg) or placebo subcutaneously once every 2 weeks. The primary end point was the annualized rate of moderate or severe exacerbations of COPD. Key secondary and other end points that were corrected for multiplicity were the change in the prebronchodilator forced expiratory volume in 1 second (FEV1) and in the scores on the St. George’s Respiratory Questionnaire (SGRQ; range, 0 to 100, with lower scores indicating a better quality of life) and the Evaluating Respiratory Symptoms in COPD (E-RS–COPD; range, 0 to 40, with lower scores indicating less severe symptoms). A total of 939 patients underwent randomization: 468 to the dupilumab group and 471 to the placebo group. The annualized rate of moderate or severe exacerbations was 0.78 (95% confidence interval [CI], 0.64 to 0.93) with dupilumab and 1.10 (95% CI, 0.93 to 1.30) with placebo (rate ratio, 0.70; 95% CI, 0.58 to 0.86; P<0.001). The prebronchodilator FEV1 increased from baseline to week 12 by a least-squares (LS) mean of 160 ml (95% CI, 126 to 195) with dupilumab and 77 ml (95% CI, 42 to 112) with placebo (LS mean difference, 83 ml; 95% CI, 42 to 125; P<0.001), a difference that was sustained through week 52. At week 52, the SGRQ score had improved by an LS mean of −9.7 (95% CI, −11.3 to −8.1) with dupilumab and −6.4 (95% CI, −8.0 to −4.8) with placebo (LS mean difference, −3.4; 95% CI, −5.5 to −1.3; P=0.002). The E-RS–COPD score at week 52 had improved by an LS mean of −2.7 (95% CI, −3.2 to −2.2) with dupilumab and −1.6 (95% CI, −2.1 to −1.1) with placebo (LS mean difference, −1.1; 95% CI, −1.8 to −0.4; P=0.001). The numbers of patients with adverse events that led to discontinuation of dupilumab or placebo, serious adverse events, and adverse events that led to death were balanced in the two groups. Among patients with COPD who had type 2 inflammation as indicated by elevated blood eosinophil counts, those who received dupilumab had fewer exacerbations, better lung function and quality of life, and less severe respiratory symptoms than those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; BOREAS ClinicalTrials.gov number, NCT03930732.) QUICK TAKE VIDEO SUMMARYDupilumab for COPD 02:17
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., McCormick, M., Haldar, K., Kebadze, T., Duvoix, A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201104-0597oc · Cited by 1,094
Self-citationSt. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0106pp · Cited by 827
Self-citationPascoe, S., Locantore, N., Dransfield, M. T., Barnes, N. C., & Pavord, I. D. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00106-x · Cited by 743
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J.-B., Sagara, H., Albers, F. C., Bradford, E. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708208 · Cited by 625
Brightling, C. E., Monteiro, W., Ward, R., Parker, D., Morgan, M. D., Wardlaw, A. J., & Pavord, I. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02872-5 · Cited by 595
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Siva, R., Green, R. H., Brightling, C. E., Shelley, M., Hargadon, B., McKenna, S., Monteiro, W., Berry, M., Parker, D., Wardlaw, A. J., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00146306 · Cited by 453
Cited by
ECM formation and degradation during fibrosis, repair, and regeneration
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 176
Metadata
- Authors
- Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Cole, J., Bafadhel, M., Christenson, S. A., Papi, A., Singh, D., Laws, E., Mannent, L. P., Patel, N., Staudinger, H. W., Yancopoulos, G. D., Mortensen, E. R., Akinlade, B., Maloney, J., Lu, X., Bauer, D., Bansal, A., Robinson, L. B., & Abdulai, R. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-20
- Volume
- 389
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4377164038
- Cited by
- 521
- References
- 24
- FWCI
- 82.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. https://app.cochat.ai/papers/10.1056/nejmoa2303951
- The paper
- Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Cole, J., Bafadhel, M., Christenson, S. A., Papi, A., Singh, D., Laws, E., Mannent, L. P., Patel, N., Staudinger, H. W., Yancopoulos, G. D., Mortensen, E. R., Akinlade, B., Maloney, J., Lu, X., Bauer, D., . . . Abdulai, R. M. (2023). Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2303951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.